56/100B366.71
USD
3.41
(0.94%)
Post Trading·366.57USD-0.14(-0.04%)
Fair value489.00Plus-25%367Price 366.71611
Q4 FY2026 · Earnings report
EPS estimate 4.50Revenue estimate 3.75B
Q4 FY2026 · Earnings report
EPS estimate 4.50Revenue estimate 3.75B
If you had invested in Laboratory ago, it would be worth $3,692 today, against $4,128 in SPY and $6,186 in QQQ.
Arincen ScoreWhat is the Arincen Score? The Arincen Score grades a company out of 100 from 30 checks on its own reported figures, five checks in each of six parts.Beta
56/100
Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.
Profitability4
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Cash6
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Valuation7.5
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Growth4
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Financial strength6
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Shareholders6
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Figures to FY2025; the price as of today.
Laboratory key facts
- StyleWhat does a stock's style mean? The style label sorts a stock as growth, value, dividend, blend or speculative, with a 1 to 10 meter showing how strongly it fits.
- Value stock · 5.7/10Growth 2.9 · Value 5.7 · Dividend 2.1
- Day range
- 359.90 – 368.99
- 52-week range
- 244.52 – 373.34
- Market capitalizationWhat is market capitalization? Market cap is what the stock market values a whole company at: its share price times the number of its shares outstanding.
- 29.78B USD
- P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 29.89
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 1.49
- EPSWhat is EPS (earnings per share)? EPS (earnings per share) is a company's net income divided by its number of shares: the profit that belongs to each share over a period.
- 12.27
- Div YieldWhat is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
- 0.79%
- EPS growth forecast (FY2026)
- +12.5%
- Volume
- 0
- BetaWhat is beta in stocks? Beta measures how much a stock tends to move when the whole market moves: 1 moves with it, under 1 is calmer, over 1 swings more.
- 0.84
- ESG scoreWhat is an ESG score? An ESG score rates how a company handles the environment, its people and its governance, out of 100. Higher is better.
- 51.5/100Environment 50 · Social 49 · Governance 56
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Adam H. Schechter
- Employees
- 71K
- Website
- labcorp.com
- IPO date
- 29 Mar 1990
Laboratory earningsWhat is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
Next earnings · Q4 FY2026
EPS estimate
4.50 USD
Revenue estimate
3.75B USD
Last quarter · Q3 FY2026
EPS4.78Beat +3.0%Revenue3.81BBeat +1.4%
Revenue
ReportedEstimate
EPS
ReportedEstimate
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|---|
| Q1 FY2028 | 5.03 | — | — | +10.68% | 3.90B | — | — | +4.49% | |
| Q4 FY2027 | 4.89 | — | — | +8.57% | 3.97B | — | — | +5.67% | |
| Q1 FY2027 | 4.54 | — | — | +6.84% | 3.73B | — | — | +5.47% | |
| Q4 FY2026 | 4.50 | — | — | +10.57% | 3.75B | — | — | +6.74% | |
| Q3 FY2026 | 4.64 | 4.78 | +3.02% | +14.35% | 3.76B | 3.81B | +1.37% | +6.92% | |
| Q2 FY2026 | 4.78 | 4.99 | +4.39% | +14.71% | 3.71B | 3.73B | +0.59% | +5.78% | |
| Q1 FY2026 | 4.11 | 4.25 | +3.41% | +10.68% | 3.51B | 3.54B | +0.82% | +5.75% | |
| Q4 FY2025 | 3.95 | 4.07 | +3.04% | +17.97% | 3.56B | 3.52B | -1.20% | +5.60% | |
| Q3 FY2025 | 4.13 | 4.18 | +1.21% | +19.43% | 3.56B | 3.56B | +0.16% | +8.58% | |
| Q2 FY2025 | 4.17 | 4.35 | +4.32% | +10.41% | 3.49B | 3.53B | +1.18% | +9.51% |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2028 | 21.64 | — | — | +9.67% | 16.43B | — | — | +5.02% |
| FY2027 | 19.74 | — | — | +6.70% | 15.64B | — | — | +5.50% |
| FY2026 | 18.50 | — | — | +12.51% | 14.83B | — | — | +6.28% |
| FY2025 | 16.33 | 16.44 | +0.66% | +12.83% | 13.99B | 13.95B | -0.29% | +7.25% |
| FY2024 | 14.52 | 14.57 | +0.33% | +4.67% | 12.99B | 13.01B | +0.17% | +0.83% |
| FY2023 | 13.54 | 13.92 | +2.83% | -29.98% | 12.15B | 12.90B | +6.22% | -13.28% |
| FY2022 | 17.07 | 19.88 | +16.43% | -30.27% | 14.94B | 14.88B | -0.44% | -7.72% |
Laboratory analyst forecastWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
12-month price target
389.89 USD
+6.32%
Analysts' 1-year price targets range from 355.00 to 420.00, with an average of 389.89.
Past year
1-year forecast
Strong sellStrong buy
Buy
9 ratings
| Buy | 7 | |
| Hold | 2 | |
| Sell | 0 |
12-month price target
| Highest target | 420.00 |
| Average target | 389.89 |
| Lowest target | 355.00 |
| Current price | 366.71 |
Laboratory valuationWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 29.89
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 19.83
- Price to sales (TTM)What is the P/S ratio? The price-to-sales ratio compares a company's market value with its revenue over the last year: what you pay for each dollar of sales.
- 2.04
- Price to bookWhat is the P/B ratio? The price-to-book ratio compares a company's market value with its book value, the shareholders' equity on its balance sheet.
- 3.37
- EV / EBITDA (TTM)What is EV/EBITDA? EV/EBITDA compares a company's whole value, debt included and cash taken off, with a year of its earnings before interest, tax and depreciation.
- 16.82
Capital structureWhat is enterprise value? Enterprise value is what the whole business costs: the market value of its shares plus its debt minus its cash. It is the price behind EV/EBITDA.
Market capitalization
29.78B USD
+
Total debt
6.78B USD
−
Cash and short-term investments
261.80M USD
=
Enterprise value
36.29B USD
Valuation over time
P/EForward P/EForward P/E · EstimateEstimate
Laboratory against its own historyWhat does "against its own history" show? The company's latest margins, return on equity, growth, debt and P/E against its own last 5 years: the low, the median and the high, and whether this year is better or worse than usual.
Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.
Its peers: Quest Diagnostics, Illumina, Mettler-Toledo International, Guardant Health, IQVIA Holdings, and Waters, the US Medical - Diagnostics & Research companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.
- P/E (today)Above its median29.97.948.4
- Gross marginLowest in 5 years26.8%26.8%38.0%Against its peers: 7 of 7Peers' median 58.6%
- Operating marginAt its median10.9%6.0%23.2%Against its peers: 6 of 7Peers' median 17.2%
- Net marginAt its median6.3%3.4%18.1%Against its peers: 6 of 7Peers' median 14.3%
- Return on equityAt its median10.2%5.3%23.1%Against its peers: 5 of 5Peers' median 23.0%
- Free cash flow marginAt its median8.6%7.2%20.2%Against its peers: 6 of 7Peers' median 14.8%
- Revenue growthHighest in 5 years7.2%-9.7%7.2%Against its peers: 3 of 7Peers' median 6.4%
- EPS growthAt its median18.3%-65.8%85.3%Against its peers: 1 of 5Peers' median 4.3%
- Debt to EBITDAAt its median3.58×1.73×4.41×Against its peers: 5 of 6Peers' median 1.89×
- Current ratioBelow its median1.421.171.92Against its peers: 4 of 7Peers' median 1.44
Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.
Laboratory growth and profitabilityWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- Revenue (TTM)What does TTM (trailing twelve months) mean? TTM (trailing twelve months) is a figure over the latest twelve months of reports: usually the last four quarters added together.
- 14.59B USD
- Net income (TTM)What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
- 1.00B USD
- Gross marginWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- 27.95%
- Operating margin
- 11.12%
- Net margin
- 6.88%
Revenue / Net income
Revenue Net income Net margin
Laboratory revenue breakdown
By product
FY2025
100.0%LabCorp Diagnostics
| Segment | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| LabCorp Diagnostics | 10.88B | 100.0% | +7.2% |
By region
FY2021
81.2%North America12.7%Europe6.1%Other countries
| Region | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| North America | 13.09B | 81.2% | +13.6% |
| Europe | 2.05B | 12.7% | +35.6% |
| Other countries | 976.40M | 6.1% | +3.8% |
How Laboratory makes its moneyWhat is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
Revenue13.95B 100.0%
Cost of revenue10.22B 73.2%
Gross profit3.73B 26.8%
Selling and administration2.22B 15.9%
Operating income1.52B 10.9%
Tax229.80M 1.6%
Other expense409.90M 2.9%
Net income876.50M 6.3%
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
Laboratory dividendsWhat is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
- Annual dividend
- 2.88 USD
- Dividend yield (indicated)What is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
- 0.79%
- Payout ratioWhat is the payout ratio? The payout ratio is the share of a company's earnings paid out as dividends: dividends per share divided by earnings per share (EPS).
- 29.34%
- Frequency
- Quarterly
- Next payment
- 0.72 USD
- Next ex-dividend dateWhat is the ex-dividend date? The ex-dividend date is the first day a stock trades without its next dividend: buy before it to receive the payment; buy on or after it and the seller gets it.
- 24 Nov 2026
- Next payment date
- 11 Dec 2026
Dividends per share
Laboratory financial health
- Cash and short-term investments
- 261.80M USD
- Total debt
- 6.78B USD
- Net cash
- -6.51B USD
- Free cash flow (TTM)What is free cash flow (FCF)? Free cash flow is the cash a company's operations bring in minus what it spends on long-term assets (capex): cash left for debt, dividends and buybacks.
- 1.29B USD
- Current ratioWhat is the current ratio? The current ratio is current assets divided by current liabilities: whether what a company will turn into cash within a year covers what it owes within a year.
- 1.41
- Debt to equityWhat is the debt to equity ratio? Debt to equity is a company's total debt divided by its shareholders' equity: how much it has borrowed for each dollar its owners have in the business.
- 0.77
- Piotroski scoreWhat is the Piotroski F-Score? The Piotroski F-Score rates a company's financial strength from 0 to 9: one point for each of nine tests of profit, debt and efficiency it passes.
- 8 / 9
- Altman Z-scoreWhat is the Altman Z-Score? The Altman Z-Score rolls five financial ratios into one number that signals a company's risk of bankruptcy: over 3 is safe, under 1.8 is distress.
- 3.52
Cash, debt and free cash flow
Cash and short-term investments Total debt Free cash flow
Laboratory ownershipWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- InstitutionsWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- 97.17%
- Institutional holders
- 1,071 (+32)
- Free floatWhat is free float? Free float is the part of a company's shares that anyone can buy and sell: all its shares minus those held by insiders, founders and owners of over 5%.
- 99.53%
Who owns the shares
Institutions 97.2% Others 2.8%
As of 30 Jun 2026
Shares free to trade
Free float 80.82M shares ·99.5% Closely held 381.64K shares ·0.5%
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Insider trading
| Quarter | Purchases | Sales | Shares acquired | Shares disposed of |
|---|---|---|---|---|
| Q4 2026 | 0 | 2 | 870.00 | 2.57K |
| Q3 2026 | 0 | 7 | 8.07K | 12.43K |
| Q2 2026 | 0 | 2 | 0.00 | 6.67K |
| Q1 2026 | 0 | 10 | 234.53K | 107.33K |
Shares outstanding
Basic shares Diluted shares Change in diluted shares
Source: Financial Modeling Prep
Title: Laboratory Corp
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.